<DOC>
	<DOCNO>NCT01769443</DOCNO>
	<brief_summary>The primary objective evaluate efficacy desensitization therapy , include VELCADE® ( bortezomib ) plasmapheresis , select sensitize patient await heart transplantation .</brief_summary>
	<brief_title>Safety Efficacy Desensitization Therapy Sensitized Participants Awaiting Heart Transplantation</brief_title>
	<detailed_description>Bortezomib work decrease plasma cell blood . Plasma cell produce antibody . Plasmapheresis procedure remove antibody blood . Plasma cell antibody produce plasma cell involve organ rejection transplantation . This trial evaluate decrease plasma cell antibody bortezomib plasmapheresis reduce complication participant wait heart transplant . The evaluation efficacy define low complication rate heart transplant waitlist .</detailed_description>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Subject must able understand provide informed consent ; Candidate ( recipient ) primary heart transplant ( single organ transplant ) ; Calculated panel reactive antibody ( cPRA ) great 30 % threshold use mean fluorescent intensity ( MFI ) 3,000 standard fluorescence intensity ( SFI ) 60,000 ; Status 1 ( 1A 1B ) enrollment randomization occur within 2 week status 1 listing ; Female subject either postmenopausal least 1 year screen visit , surgically sterilize childbearing potential , agree practice 2 effective method contraception time sign informed consent form 30 day last dose bortezomib , agree completely abstain heterosexual intercourse ; Male subject , even surgically sterilize ( i.e. , status postvasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse ; Negative test HIV ( human immunodeficiency virus ) , HBsAg ( hepatitis B surface antigen ) , HBcAb ( hepatitis B core antibody ) , HCV ( hepatitis C virus ) antibody within 6 month prior study entry . Recipient multiple solid organ tissue transplant ; Prior history organ transplantation ; Women childbearing potential positive serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test.Pregnancy test require postmenopausal surgically sterilized woman ; Currently breastfeed child plan become pregnant timeframe study followup period ; Subject hypersensitivity VELCADE® ( bortezomib ) , boron , mannitol ; Active systemic infection time enrollment ; Any history serologic positivity HIV , HBsAg , HBcAb HCV Ab ; History malignancy except noted oncology specialist tumor recurrence low base tumor type , response therapy negative metastatic workup ; Radiation therapy within 3 week randomization . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy ; Subjects platelet count le 75,000 within 7 day prior enrollment ; Subjects absolute neutrophil count ( ANC ) less 1,500 within 7 day prior enrollment ; Subjects &gt; 1.5 x ULN ( upper limit normal ) total bilirubin ; Subjects grade history neuropathy ; Any condition , opinion investigator , would interfere subject 's ability comply study requirement ; Participation another interventional clinical trial require treatment use unmarketed investigational drug ( ) within 14 day start trial throughout duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>desensitization therapy</keyword>
	<keyword>bortezomib ( VELCADE® )</keyword>
	<keyword>plasmapheresis</keyword>
</DOC>